LRPPRC gene replacement therapy preserves cardiac function and prevents premature death in a mouse model of mitochondrial disease
Authors: S. Zanin, F. Lager, M. Simon-Sola, C. Gaborit, G. Renault, F. Mingozzi, A. Rotig, M. Cavazzana, M. Metodiev, B. Ruzzenente
Abstract
Pathogenic variants in LRPPRC disrupt mitochondrial gene expression, causing severe and incurable mitochondrial disease with neurological involvement accompanied by hepatopathy or cardiomyopathy. The development for gene therapy for LRPPRC-linked disease is hindered by the large LRPPRC coding sequence exceeding AAV cargo capacity when combined with classical regulatory elements. Here, we engineered compact single rAAV9 vectors expressing human or mouse LRPPRC and administered them intravenously to heart and skeletal muscle-specific Lrpprc knockout mice. This approach restored cardiac LRPPRC expression, preserved oxidative phosphorylation (OXPHOS) function, prevented cardiomyopathy and markedly extended survival. While skeletal muscle rescue was partial, the therapy effectively prevented fatal cardiac dysfunction. These findings provide the first in vivo proof-of-concept that AAV-mediated LRPPRC gene replacement can preserve OXPHOS function and prevent lethal cardiomyopathy, supporting its potential as a therapeutic strategy for mitochondrial disease linked to LRPPRC deficiency.
The papers around it, by date and closeness
Higher is closer to this paper; left is older. Lines join papers close to each other: groups of lines are sub-topics. Select a point to see why it is there. Back to the summary of this paper
Papers around this one
Ranked by how close their title and abstract are to this paper’s. Select some to read them together.
Closest papers
-
PKR drives neuropathology in a mouse model of Leigh syndromeM. Gonzalez-Torres, P. Bianchi, M. Blanco-Ramos et al. · 2026 · bioRxiv preprint · AI summary available
PKR drives mitochondrial neuropathology in Ndufs4-deficient Leigh syndrome mice, whereas this paper uses Lrpprc deficiency to study cardiac disease and gene replacement.
In short
PKR contributes to neurological decline and inflammation in Ndufs4-deficient mice, and its removal delays disease without restoring mitochondrial respiration.
-
Prevention of prion disease symptoms in mice with deep PrP loweringJ. E. Gentile, J. E. Farley, M. N. Kelemen et al. · 2026 · bioRxiv preprint · AI summary available
This study lowers PrP with siRNA to prevent prion symptoms in mice, rather than replacing a mitochondrial disease gene with AAV.
In short
Deep PrP lowering with a C16-conjugated siRNA prevented symptoms through 500 days in prion-infected mice treated early and extended survival when treatment began after symptoms.
-
Nationwide Functional Profiling Enables Clinical Reclassification of KCNH2 Variants in the French LQT2 PopulationB. Ribeiro de Oliveira, M. Alameh, S. Feliciangeli et al. · 2026 · medRxiv preprint · AI summary available
In short
Standardized functional profiling of 303 French KCNH2 variants integrated with MeTAL modeling and calibrated ACMG evidence to reclassify 64 VUS.
-
Phosphatidylserine receptors are critical for lethal infection by Crimean-Congo hemorrhagic fever virusJ. Berrigan, S. R. Monticelli, M. D. Ramirez et al. · 2026 · bioRxiv preprint · AI summary available
This study blocks phosphatidylserine receptors to protect mice from viral disease, unlike this paper’s AAV treatment for LRPPRC-deficient cardiomyopathy.
In short
AXL, TIM-1, and TIM-4 support CCHFV entry and disease; deleting two receptors protected mice in a lethal-challenge model.
-
CSF PrP-amyloid seeding predicts clinical onset in inherited prion diseaseT. H. Mok, A. Nihat, S. M. Vallabh et al. · 2026 · medRxiv preprint · AI summary available
This study tests whether CSF prion seeding predicts clinical onset in mutation carriers, while this paper evaluates gene replacement in a mouse model.
In short
In PRNP E200K carriers, CSF RT-QuIC positivity preceded clinical onset and marked substantially elevated near-term conversion risk.
-
Stem Cell Therapy for Alzheimer's DiseaseAnkur Patel, Grishma joshi, Rupali Ugile · 2016 · Neurons and Cognition · preprint, not peer reviewed · cited 88 times · AI summary available
This review discusses stem cell therapy for Alzheimer’s disease, rather than AAV-mediated LRPPRC replacement for mitochondrial cardiomyopathy.
Abstract
The loss of neuronal cells in the central nervous system may happen in numerous neurodegenerative illnesses. Alzheimer's Disease (AD) is an intricate, irreversible, dynamic neurodegenerative sickness. It is the main source of age-related dementia, influencing roughly 5.3 million individuals in the United States alone. Promotion is a typical feeble ailment in individuals more than 65 years, bringing on disability described by decrease in memory, failure to learn and do every day exercises, intellectual weakness and influences the personal satisfaction of patients. Pathologic qualities of AD are an irregular development of specific proteins called Beta-amyloid "plaques" and Tau "Tangles" in th…
-
Genome analysis and pleiotropy assessment using causal networks with loss of function mutation and metabolomicsAzam Yazdani, Akram Yazdani, Sarah H. Elsea et al. · 2019 · Genomics · cited 25 times · AI summary available
This study links loss-of-function mutations to serum metabolites using causal networks, whereas this paper tests LRPPRC gene replacement in knockout mice.
Abstract
Background: Many genome-wide association studies have detected genomic regions associated with traits, yet understanding the functional causes of association often remains elusive. Utilizing systems approaches and focusing on intermediate molecular phenotypes might facilitate biologic understanding. Results: The availability of exome sequencing of two populations of African-Americans and European-Americans from the Atherosclerosis Risk in Communities study allowed us to investigate the effects of annotated loss-of-function (LoF) mutations on 122 serum metabolites. To assess the findings, we built metabolomic causal networks for each population separately and utilized structural equation mode…
-
Robin: A multi-agent system for automating scientific discoveryAli Essam Ghareeb, Benjamin Chang, Ludovico Mitchener et al. · 2025 · Artificial Intelligence · preprint, not peer reviewed · cited 91 times · AI summary available
Robin automates scientific discovery workflows, while this paper experimentally tests gene replacement in a mouse model of mitochondrial disease.
Abstract
Scientific discovery is driven by the iterative process of background research, hypothesis generation, experimentation, and data analysis. Despite recent advancements in applying artificial intelligence to scientific discovery, no system has yet automated all of these stages in a single workflow. Here, we introduce Robin, the first multi-agent system capable of fully automating the key intellectual steps of the scientific process. By integrating literature search agents with data analysis agents, Robin can generate hypotheses, propose experiments, interpret experimental results, and generate updated hypotheses, achieving a semi-autonomous approach to scientific discovery. By applying this sy…
Go further
How are these papers found?
We compare the title and abstract of this paper with those of every paper summarized on this site, and with the papers Semantic Scholar recommends, those it cites and those citing it (for a much-cited paper, its most recent citations and, from OpenAlex, the most cited ones). Among the prior work and the follow-ups, the papers that use each other in depth, a method it uses and the much-cited follow-ups come a little higher. The levels (very close, close, related) come from the similarity of the texts, not from a judgment of quality; * marks a paper without an abstract, compared by its title. The sentence under a paper is written by an AI from the two abstracts: check it in the papers. A paper marked not relevant by three readers leaves the list.
Updated on 16 November 2026.